Around 5% of non-small-cell lung cancer patients using osimertinib monotherapy may experience severe cardiac adverse events, suggests a study of Japanese patients.
The risk for acquiring SARS-CoV2 infection appears to be more than twofold higher for people with cancer than the general community, indicates a chart review.
Carboplatin–pemetrexed plus pemetrexed maintenance is noninferior to docetaxel for the first-line treatment of advanced non-small-cell lung cancer in patients aged 75 years or older, suggests a phase 3 Japanese study.